With Covid sales declining, Pfizer zeroes in on M&A and oncology

Tyler Patchen

News Reporter

Pfizer’s first-quarter revenue tumbled, as expected, due to dwindling sales of its Covid-19 products, yet executives sought to reinforce the company’s renewed focus on cancer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With Covid sales declining, Pfizer zeroes in on M&A and oncology

Tyler Patchen

News Reporter

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Roivant brings rare disease program closer as Immunovant CEO retires

China startup injects CRISPR therapy into the brain for the first time

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

With Covid sales de­clin­ing, Pfiz­er ze­roes in on M&A and on­col­o­gy

News Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

With Covid sales declining, Pfizer zeroes in on M&A and oncology